Parenteral Calcitonin for Metabolic Bone Disease Associated With Primary Biliary Cirrhosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
No satisfactory treatment is available for metabolic bone disease associated with primary biliary cirrhosis. On the basis of the similarities to postmenopausal osteoporosis, the rationale exists for calcitonin to be tested in clinical studies in patients with primary biliary cirrhosis—associated osteoporosis. We evaluated the effect of calcitonin on bone metabolism and mineral density in 25 women with primary biliary cirrhosis and severe osteopenia. After 6 mo of observation, patients received a synthetic calcitonin or a control treatment consisting of less than one hundredth of the recommended dose of porcine calcitonin. The two treatments were administered in sequence to each patient for two 6–mo periods, with a 3–mo washout between them, according to a crossover design. After the observation period, oral calcium supplementation was started. Bone mineral density was measured by dual–photon absorptiometry of the lumbar spine at study entry and at the beginning and the end of each treatment period. During the observation period bone mineral density fell by 3.5% whereas during the following 6 mo it increased in both the patients who received calcitonin (4.3%) and those who received the control treatment (4.9%). Conversely, after the crossover, bone mineral density decreased during both calcitonin (–2.7%) and control treatment (–2.9%). A significant difference was observed between the two periods but not between the two treatments or between the two sequences of treatment administration. In conclusion, our findings indicate that parenterally administered calcitonin for 6 mo is ineffective in halting bone loss in patients with primary biliary cirrhosis—associated metabolic bone disease, whereas calcium supplementation may have a transient beneficial effect. (Hepatology 1994;20:633-637).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Two-Period Change-Over Design and Its Use in Clinical Trials
Grizzle, J. E. (1965) · Biometrics · doi:10.2307/2528104 · Cited by 784
Eastell, R., Dickson, R. E., Hodgson, S. F., Wiesner, R. H., Porayko, M. K., Wahner, H. W., Cedel, S. L., Riggs, L. B., & Krom, R. A. F. (1991) · Hepatology · doi:10.1002/hep.1840140215 · Cited by 297 · cited 4×
“The reported similarities in histologic features and high bone turnover in postmenopausal and PBC-associated osteoporosis (7, 8) constitute a rationale for testing calcitonin in clinical studies on the PBC-associated form of metabolic bone disease.”
BackgroundResultInfluentialThe Two-Period Crossover Design in Medical Research
Woods, J. R., Williams, J. G., & Tavel, M. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-560 · Cited by 139 · cited 1×
“which allowed each patient to act as her own control (24, 27).”
BackgroundMorikawa, T., Munekata, E., Sakakibara, S., Noda, T., & Otani, M. (1976) · Experientia · doi:10.1007/bf01927568 · Cited by 95
Research works printed but not linked: 31
- Hodgson, 1985, Ann Intern Med, 103, 855, 10.7326/0003-4819-103-6-855 · DOI · Paper page
- Almdal, 1989, J Intern Med, 225, 207, 10.1111/j.1365-2796.1989.tb00065.x · doi:10.1111/j.1365-2796.1989.tb00065.x
- Matloff, 1982, Gastroenterology, 83, 97, 10.1016/S0016-5085(82)80291-6 · DOI · Paper page
- Stellon, 1985, Q J Med, 223, 783
- Bone disease in patients with primary biliary cirrhosis. In: , eds. Progress in liver disease. Philadelphia: WB Saunders, 1990: 537–554.
- Stellon, 1987, Hepatology, 7, 137, 10.1002/hep.1840070127 · DOI · Paper page
- Mitchison, 1988, Gastroenterology, 94, 463, 10.1016/0016-5085(88)90438-6 · DOI
- Berg, 1992, Scand J Gastroenterol, 192, 43, 10.3109/00365529209095978 · DOI
- McDonald, 1991, Hepatology, 14, 613, 10.1002/hep.1840140407 · DOI · Paper page
- Wagonfeld, 1976, Lancet, 2, 391, 10.1016/S0140-6736(76)92407-7 · DOI
- Compston, 1979, Gut, 20, 133, 10.1136/gut.20.2.133 · DOI
- Davies, 1983, Dig Dis Sci, 28, 145, 10.1007/BF01315144 · DOI
- Herlong, 1982, Gastroenterology, 83, 103, 10.1016/S0016-5085(82)80292-8 · DOI · Paper page
- Arnaud, 1982, Gastroenterology, 83, 137, 10.1016/S0016-5085(82)80299-0 · DOI
- Gruber, 1984, Metabolism, 33, 295, 10.1016/0026-0495(84)90187-2 · DOI · Paper page
- MacIntyre, 1988, Lancet, 1, 900, 10.1016/S0140-6736(88)91712-6 · DOI · Paper page
- Reginster, 1991, Am J Med, 91, 19, 10.1016/0002-9343(91)90242-P · DOI
- Floreani, 1991, J Hepatol, 12, 217, 10.1016/0168-8278(91)90941-4 · DOI
- Camisasca, 1990, Hepatology, 12, 841
- Nuti, 1984, Calcif Tissue Int, 36, 76
- Mazzuoli, 1986, Calcif Tissue Int, 38, 3, 10.1007/BF02556587 · DOI · Paper page
- Wahner, 1985, Radiology, 156, 203, 10.1148/radiology.156.1.4001406 · DOI · Paper page
- Johnston, 1991, N Engl J Med, 324, 1105, 10.1056/NEJM199104183241606 · DOI · Paper page
- . Handbook of statistical tables. Reading, MA: Addison-Wesley, 1962.
- Rodysill, 1987, A review. J Chron Dis, 40, 743, 10.1016/0021-9681(87)90126-3 · DOI
- Prince, 1991, A comparative study of exercise, calcium supplementation and hormone-replacement therapy. N Engl J Med, 325, 1189
- Dawson-Hughes, 1990, N Engl J Med, 323, 878, 10.1056/NEJM199009273231305 · DOI · Paper page
- Heaney, 1991, Am J Med, 91, 23, 10.1016/0002-9343(91)90243-Q · DOI
- Sambrook, 1993, N Engl J Med, 328, 1747, 10.1056/NEJM199306173282404 · DOI · Paper page
- Bikle, 1983, Ann Intern Med, 98, 1013, 10.7326/0003-4819-98-6-1013 · DOI
- Storm, 1990, N Engl J Med, 322, 1265, 10.1056/NEJM199005033221803 · DOI · Paper page
Cited by
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Management of primary biliary cirrhosis
Heathcote, J. E. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 417
Guidelines on the management of osteoporosis associated with chronic liver disease
Collier, J. D., Ninkovic, M., & Compston, J. E. (2002) · Gut · doi:10.1136/gut.50.suppl_1.i1 · Cited by 241
Rouillard, S., & Lane, N. E. (2001) · Hepatology · doi:10.1053/jhep.2001.20533 · Cited by 125
Ninkovic, M., Love, S. A., Tom, B., Alexander, G. J. M., & Compston, J. E. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-2028-4 · Cited by 123
“Few studies are available on the treatment of bone disease in patients with liver disease, although there is some evidence that bisphosphonates [35] and estrogens [34] may be beneficial, whereas calcitonin [36] and sodium fluoride [35]do not appear to have significant effects on bone mineral density.”
BackgroundLeuschner, M., Güldütuna, S., You, T., Hübner, K., Bhatti, S., & Leuschner, U. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80327-8 · Cited by 119
Guañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., et al. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07639.x · Cited by 119
Osteoporosis in liver diseases and after liver transplantation
Hay, J. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00143-0 · Cited by 72
“Histomorphometric studies with paired biopsies before and 3–4 months after OLT have tried to elucidate the underlying mechanism of bone loss and recovery ([85], #301, [86], #344, [87], #388).”
BackgroundGuañabens, N., & Parés, A. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.030 · Cited by 71
Diagnosis and Management of Cirrhosis-Related Osteoporosis
Santos, L. A. A., & Romeiro, F. G. (2016) · BioMed Research International · doi:10.1155/2016/1423462 · Cited by 66
Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment
Parés, A., & Guañabens, N. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.005 · Cited by 63
Levy, C., Harnois, D. M., Angulo, P., Jorgensen, R., & Lindor, K. D. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01026.x · Cited by 62
Management of osteoporosis in liver disease
Guañabens, N., & Parés, A. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.03.007 · Cited by 56
Osteoporosis in primary biliary cholangitis
Danford, C. J., Trivedi, H. D., Papamichael, K., Tapper, E. B., & Bonder, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3513 · Cited by 56
Boone, R. H., Cheung, A. M., Girlan, L. M., & Heathcote, E. J. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-8015-x · Cited by 54
Treatment of bone disorders in liver disease
Parés, A., & Guañabens, N. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.007 · Cited by 50
“However, other studies have described negative results since the administration of calcitonin over 6 months was unable to prevent the loss of trabecular bone, although it should be taken into account that the patients studied had severe osteopenia and were treated for a very short period of time [82].”
ResultPatel, N., & Muñoz, S. J. (2015) · Clinical Liver Disease · doi:10.1002/cld.498 · Cited by 34
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease
Yurci, A., Kalkan, A. O., Ozbakir, O., Karaman, A., Torun, E., Kula, M., Baskol, M., Gursoy, S., Yucesoy, M., & Bayram, F. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834cd6f6 · Cited by 22
Metadata
- Authors
- Crosignani, A., Battezzati, P. M., Albisetti, W., Grandinetti, G., Pietrogrande, L., Biffi, A., Zuin, M., & Podda, M.
- Venue
- Hepatology
- Published
- 1994-09
- Volume
- 20
- Issue
- 3
- Pages
- 633-637
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1996983302
- Cited by
- 73
- References
- 4
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 7670 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.